30 Day Trial

Viseon Spine Closes $5 Million Series A Financing


Viseon Spine closed a US $5.0MM Series A financing. Funds will support product development, worldwide regulatory approvals, clinical evaluations, manufacturing and commercialization as the company develops single-use, disposable visualization and illumination technologies for minimally invasive spine surgery.

Viseon's systems are intended for use in a range of posterior cervical, thoracic and lumbar procedures, including advanced lateral access MIS, replacing microscopes, endoscopes and high capital equipment. 

Viseon was founded in early 2017 as a spin-off from Rebound Therapeutics, which is developing MIS imaging and visualization tools for an array of procedures including neuro and orthopaedic. Viseon is armed with 13 patents and a completed series of pre-clinical studies that support initial human use. Financing was led by HBM-MedFocus, Invus Opportunities Fund and affiliates of Wexford Capital.

Source: Viseon Spine Incorporated

In anticipation of new devices to be launched at NASS, ORTHOKNOW® asked James F. Marino, M.D., a thought leader in MIS and founder of NuVasive and Trinity Orthopedics, about minimally invasive surgical technologies.

ORTHOKNOW: What is the role of device companies in the progression of MIS?

Dr. Marino: Device companies have numerous challenges to overcome, to ensure that they first survive and then hopefully thrive. Ultimately, the advancement of MISS innovative solutions is a requirement for all spine device companies, because that has been the trend in all surgical disciplines for at least the last 40 years. This is particularly true for the smaller entities, as they can only garner attention, acquisition or significant market share if they conceive, develop and introduce novel MISS procedures and enabling instrumentation. 

Hear more from Dr. Marino in ORTHOKNOW.